Moreover, to achieve regularity and higher replicative efficiencyin vivo, these SHIVs have been extensively passaged in monkeys. these three new clade C SHIVs will provide biologically relevant assessments for vaccine protection in rhesus macaques. Keywords:SHIV, HIV-1 Clade C, Transmitted/founder Env, Mucosal transmission == INTRODUCTION == Chimeric simian-human immunodeficiency viruses (SHIVs) were developed for Rabbit Polyclonal to RPS23 studies of pathogenicity and preclinical assessment of candidate HIV-1 vaccines in nonhuman primate (NHP) models (Sato and Johnson, 2007). Chimeric viruses that contain HIV-1tat, rev, vpuandenv genes,with the remainder of the computer virus originating from the simian immunodeficiency computer virus (SIV), have been used as challenge viruses to assess the ability of HIV-1 envelope glycoprotein (Env)-based vaccines to elicit antibodies that prevent contamination. However, currently available SHIV challenge stocks have limitations. Many HIV-1 Envs do not produce viable viruses when introduced into the SIV backbone. One of the first SHIVs to be generated that replicated robustly in rhesus monkeys and caused an AIDS-like illness was SHIV-89.6P (Reimann et al., 1996a;Reimann et al., 1996b). However, this dual-tropic (CXCR4/CCR5-tropic) computer virus exhibitedin vivopreference for CXCR4, unlike the CCR5-tropism of transmitted HIV-1 variants; thus, in infected monkeys, SHIV 89.6P preferentially targeted nave CD4+ T cells, a situation very different from acute HIV-1 infection in humans (Igarashi et al., 2003;Nishimura et al., 2004). SHIVs with exclusively CCR5-tropic envelopes have been generated; however viral loads and CD4+ T cell loss in animals infected with these SHIVs have been variable (Pahar et al., 2007;Pal et al., 2003;Parren et al., 2001;Tan et al., 1999). The Envs of currently utilized SHIVs for which challenge stocks are available, such as SHIV SF162P3 (Harouse et al., 1999) and SHIV BaLP4 (Pal et al., 2003), were isolated from individuals chronically infected with HIV-1. As a result, these Envs were AS-1517499 exposed to considerable humoral and cellular immune pressure within the infected individuals from whom they were isolated. Moreover, to achieve regularity and higher replicative efficiencyin vivo, these SHIVs have been extensively passaged in monkeys. There is evidence from HIV-infected humans and SIV-infected rhesus monkeys that viralenvgenes accrue mutations during the course of infection that AS-1517499 allow them to escape from AS-1517499 autologous neutralizing antibodies (Mikell et al.;Moore et al., 2009;van Gils et al.;Yeh et al.). It is thus likely that this neutralization sensitivities of the chronic Envs used in current SHIVs are different from those of the transmitted/ founder (T/F) viruses that establish infections in humans, and use of SHIVs that contain such chronic Envs may bias the results of antibody protection studies in NHP. A recent manuscript describes development of a new CCR5-tropic SHIV expressing T/F Env from HIV-1 Clade B (Del Prete et al., 2014). Both dual-tropic and CCR5-tropic SHIVs made up of Envs from clade C HIV-1 have previously been reported (Cayabyab et al., 2004;Chen et al., 2000;Humbert et al., 2008;Ren et al., 2013;Siddappa et al., 2009;Track et al., 2006). Some of these CCR5-tropic, clade C SHIVs encodedenvgenes that were isolated from recently infected subjects (Humbert et al., 2008;Ren et al., 2013). However, these SHIVs have been passaged extensively in monkeys. Therefore, the envelopes encoded in these SHIVs may have undergone sequence alterations compared with the parental envelopes in the T/F viruses. We hypothesized that SHIVs made up of T/F HIV-1envgenes would be able to better recapitulate the mucosal transmission physiology of acute HIV infection, and thus more accurately reflect the sensitivity of transmitted HIV-1 Envs to antibody-mediated neutralization. Approximately 80% of individuals who are infected via heterosexual contact are infected by one founder computer virus (Keele et al., 2008). One of the early pathogenic SHIVs, KB9, began with the introduction oftat, rev, vpuandenvgenes from a chronic clade B HIV-189.6into the SIVmac239 backbone. The producing computer virus was passaged in monkeys to produce the pathogenic SHIV 89.6P; SHIV KB9 is an AS-1517499 infectious, pathogenic molecular proviral clone derived from SHIV 89.6P-infected cells (Karlsson et al., 1997). Because KB9 was a viable SHIV, we utilized the KB9 architecture to generate novel SHIVs with theenvgenes of CCR5-tropic, Clade C T/F HIV-1 from acutely infected individuals from South Africa. Three clade C SHIVs with T/F Envs that are phylogenetically diverse infected rhesus macaques after atraumatic mucosal exposure. These three clade C SHIVs are the first clade C SHIVs that encodeenvgenes isolated from T/F viruses at the earliest stages of contamination (Parrish et al., 2012). Clade C is the major infecting subtype of HIV-1 infections globally. Our results provide insights AS-1517499 into the ability of Clade C T/F Envs to mediate mucosal.